Emily AF Holmes

Dr. Emily AF Holmes

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2014 in Value in Health
Verified
Journal Article
Closed access
EHEmily AF Holmes
Emily AF Holmes
DHDyfrig Hughes
Dyfrig Hughes
VMValerie L. Morrison
Valerie L. Morrison

1 March 2015 in Value in Health
Verified
Journal Article
Closed access
VMValerie L. Morrison
Valerie L. Morrison
EHEmily AF Holmes
Emily AF Holmes
SPSahdia Parveen
Sahdia Parveen
CPCatrin O. Plumpton
Catrin O. Plumpton
WCWendy Clyne
Wendy Clyne
DHDyfrig Hughes
Dyfrig Hughes

7 December 2018 in Antibiotics
Verified
Journal Article
Open access
PDF file
EHEmily AF Holmes
Emily AF Holmes
SHSharman D. Harris
Sharman D. Harris
AHAlison Hughes
Alison Hughes
NCNoel Craine
Noel Craine
DHDyfrig Hughes
Dyfrig Hughes
More appropriate and measured use of antibiotics may be achieved using point-of-care (POC) C-reactive protein (CRP) testing, but there is limited evidence of cost-effectiveness in routine practice. A decision analytic model was developed to estimate the cost-effectiveness of testing, compared with standard care, in adults presenting in primary care with symptoms of acute respiratory tract infection (ARTI). Analyses considered (1) pragmatic use of testing, reflective of routine clinical practice, and (2) testing according to clinical guidelines. Threshold and scenario analysis were performed to identify cost-effective scenarios. In patients with symptoms of ARTI and based on routine practice, the incremental cost-effectiveness ratios of CRP testing were £19,705 per quality-adjusted-life-year (QALY) gained and £16.07 per antibiotic prescription avoided. Following clinical guideline, CRP testing in patients with lower respiratory tract infections (LRTIs) cost £4390 per QALY gained and £9.31 per antibiotic prescription avoided. At a threshold of £20,000 per QALY, the probabilities of POC CRP testing being cost-effective were 0.49 (ARTI) and 0.84 (LRTI). POC CRP testing as implemented in routine practice is appreciably less cost-effective than when adhering to clinical guidelines. The implications for antibiotic resistance and Clostridium difficile infection warrant further investigation.

11 January 2016 in PharmacoEconomics
Verified
Journal Article
Closed access
PDF file
DHDyfrig Hughes
Dyfrig Hughes
JCJoanna Charles
Joanna Charles
DDDalia Dawoud
Dalia Dawoud
RERhiannon Tudor Edwards
Rhiannon Tudor Edwards
EHEmily AF Holmes
Emily AF Holmes
SYSeow Tien Yeo
Seow Tien Yeo

1 February 2019 in Seizure: European Journal of Epilepsy
Verified
Journal Article
Closed access
EHEmily AF Holmes
Emily AF Holmes
SBSiobhan Bourke
Siobhan Bourke
CPCatrin Plumpton
Catrin Plumpton

22 August 2015 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
GPGraham Powell
Graham Powell
EHEmily AF Holmes
Emily AF Holmes
CPCatrin O. Plumpton
Catrin O. Plumpton
ARAdele Ring
Adele Ring
GBGus A. Baker
Gus A. Baker
DHDyfrig Hughes
Dyfrig Hughes
Aim: Pharmacogenetic studies have identified the presence of the HLA‐A*31:01 allele as a predictor of cutaneous adverse drugs reactions (ADRs) to carbamazepine. This study aimed to ascertain the preferences of patients and clinicians to inform carbamazepine pharmacogenetic testing services.Methods: Attributes of importance to people with epilepsy and neurologists were identified through interviews and from published sources. Discrete choice experiments (DCEs) were conducted in 82 people with epilepsy and 83 neurologists. Random‐effects logit regression models were used to determine the importance of the attributes and direction of effect.Results: In the patient DCE, all attributes (seizure remission, reduction in seizure frequency, memory problems, skin rash and rare, severe ADRs) were significant. The estimated utility of testing was greater, at 0.52 (95% CI 0.19, 1.00) than not testing at 0.33 (95% CI –0.07, 0.81). In the physician DCE, cost, inclusion in the British National Formulary, coverage, negative predictive value (NPV) and positive predictive value (PPV) were significant. Marginal rates of substitution indicated that neurologists were willing to pay £5.87 for a 1 percentage point increase in NPV and £3.99 for a 1 percentage point increase in PPV.Conclusion: The inclusion of both patients' and clinicians' perspectives represents an important contribution to the understanding of preferences towards pharmacogenetic testing prior to initiating carbamazepine. Both groups identified different attributes but had generally consistent preferences. Patients' acceptance of a decrease in treatment benefit for a reduced chance of severe ADRs adds support for the implementation of HLA‐A*31:01 testing in routine practice.